A battered Zafgen seeks strategic options, prophesying ongoing study will unlikely lift FDA hold on diabetes drug
Zafgen, which back in 2015 crossed the $50 mark, is now firmly in penny stock territory. Blighted by safety concerns across a range of its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
